Stock BCLI BRAINSTORM CELL THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Brainstorm Cell Therapeutics Inc.

Equities

BCLI

US10501E2019

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.5345 USD +0.47% Intraday chart for Brainstorm Cell Therapeutics Inc. +0.47% +95.79%
Apr. 17 Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024 CI
Apr. 17 Brainstorm Cell Therapeutics Inc. Announces Management Changes CI

Evolution of the average Target Price on Brainstorm Cell Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

e6e7.g2O1cNc7Hi67lmIbWpdFqN-rqTQK6ufPjE4wrTddY9o.2i3EL7NBSxnJ5yYoLeAg5YD9xVVHm9S5xDtamnwJIeqzW_oCnGRmb4vuJw~7059661bd2a164fb0694cfe32fe93acd

Analyst Recommendations on Brainstorm Cell Therapeutics Inc.

Maxim Downgrades Brainstorm Cell Therapeutics to Hold From Buy MT
Fed rates at 7%: Is it on the cards? Our Logo
Maxim Group Adjusts Price Target on Brainstorm Cell Therapeutics to $10 From $5, Maintains Buy Rating MT
BRAINSTORM CELL THERAPEUTICS : Maxim Group Upgrades Brainstorm Cell Therapeutics to Buy From Hold MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.5345 USD
Average target price
2.5 USD
Spread / Average Target
+367.73%
High Price Target
2.5 USD
Spread / Highest target
+367.73%
Low Price Target
2.5 USD
Spread / Lowest Target
+367.73%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Brainstorm Cell Therapeutics Inc.

Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BCLI Stock
  4. Consensus Brainstorm Cell Therapeutics Inc.